Jiage Qian

Jiage Qian

Auto-generated profile, based on publicly available information

Jiage Qian

University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
JQJiage Qian
Jiage Qian
CWCarrie Wolfson
Carrie Wolfson
BKBriana Kramer
Briana Kramer
ACAndreea A. Creanga
Andreea A. Creanga

27 May 2025 in HPB
Verified
Journal Article
Open access
JAJurgis Alvikas
Jurgis Alvikas
AHAhmed Hamed
Ahmed Hamed
NTNikhil Tirukkovalur
Nikhil Tirukkovalur
SCSebastiaan Ceuppens
Sebastiaan Ceuppens
ATAdam Tcharni
Adam Tcharni
APAlessandro Paniccia
Alessandro Paniccia
CA 19-9 is the most commonly used biomarker for pancreatic ductal adenocarcinoma (PDAC) but prognostication is a challenge for patients with normal CA 19-9 levels. We aimed to define most important prognostic factors for overall survival in PDAC patients with normal range CA 19-9 levels. We performed a single-center retrospective review of PDAC patients with CA 19-9 level at diagnosis <37 U/mL who underwent curative intent resection. Cohort was divided into CA 19-9 non-producers (CA 19-9 level of <3 U/mL) and normal range CA 19-9 (between 3 U/mL and 37 U/mL). We used a multivariable Cox regression model to define the predictors of overall survival and constructed a nomogram. 271 patients were included (75 CA 19-9 non-producers and 196 with normal range CA 19-9). Non-producers had worse overall survival (27.2 months versus 33.6 months) and higher rate of recurrence after resection. Predictors of survival were CA 19-9 level, age, sex, lymph node ratio, perineural invasion, surgical margin status and adjuvant chemotherapy. PDAC patients who are CA 19-9 non-producers have worse survival. Our findings highlight this high-risk subgroup, identify useful prognostic features and emphasize the ongoing need for improved biomarker development.

11 May 2023 in Journal of Global Health Reports
Verified
Journal Article
Open access
PDF file
JQJiage Qian
Jiage Qian
SSSolomon Shiferaw
Solomon Shiferaw
ASAssefa Seme
Assefa Seme
OEOusman E. Esmale
Ousman E. Esmale
WDWubshet Denboba
Wubshet Denboba
ACAndreea A. Creanga
Andreea A. Creanga
Background: Well-functioning health management information systems (HMIS) enable decision-making at all health system levels. This study develops an index to measure the use of HMIS data at the facility level. Methods: We used two rounds of cross-sectional data collected from 305 health facilities in Ethiopia in 2019 (pre-COVID-19) and 2020 (post-COVID-19). We constructed a summative, 10-item index using exploratory factor analysis and 2019 index development data; and used Cronbach’s alpha to assess reliability. To examine content validity, we mapped items against a previously published conceptual framework and consulted Ethiopian experts. We then employed one-way ANOVA and t-tests comparing the mean index scores overall and by key facility characteristics between 2019 and 2020. Results: The 10-item index loaded on one factor (Cronbach’s alpha=0.74), and the index scores did not differ significantly by facility characteristics in 2019. The mean index score increased from 7.2 in 2019 to 7.9 in 2020 (P<0.01). During this period, more facilities received feedback on HMIS reports from facility leadership (19.3% difference); received actionable recommendations on performance targets and resource allocation (7.5% and 12.3% difference, respectively); and reviewed maternal deaths (15.1% difference); conversely, the proportion of facilities that held participatory performance review meetings monthly or more often decreased by 13.8% (all P <0.05). Conclusions: We propose a facility-level HMIS data use index and document an upward trend in HMIS data use in Ethiopia immediately after the COVID-19 pandemic was declared. Future research should further evaluate and refine the proposed index to support the measurement of HMIS data quality and utilization in Ethiopia and like settings.

29 May 2025 in Journal of Surgical Research
Verified
Journal Article
Open access
JQJiage Qian
Jiage Qian
NTNikhil V. Tirukkovalur
Nikhil V. Tirukkovalur
SCSebastiaan Ceuppens
Sebastiaan Ceuppens
ASAatur Singhi
Aatur Singhi
KLKenneth K. Lee
Kenneth K. Lee
APAlessandro Paniccia
Alessandro Paniccia
Pancreatic acinar cell carcinoma (pACC) and pancreatoblastoma (PBL) are rare pancreatic neoplasms with overlapping clinical and histological features. This study aims to compare the clinical presentation, treatment strategies, and survival outcomes of pACC and PBL using data from the National Cancer Database. Data from the National Cancer Database (2004-2019) were analyzed for adult patients with pACC (n = 1416) and PBL (n = 32). Overall survival (OS) was assessed using Kaplan-Meier curves and log-rank tests. Multivariate Cox proportional hazards models evaluated factors impacting survival. Both tumors commonly presented in the pancreatic head (40.6% PBL, 41.2% pACC, P = 0.99) with high rates of stage four disease (53.1% PBL, 46.5% pACC, P = 0.25). PBL exhibited higher neoadjuvant chemotherapy use (30.0% versus 13.6%, P = 0.038) and surgical resection rates (68.8% versus 41.0%, P = 0.002). The median OS was 59.8 months for PBL and 22.8 months for pACC (P = 0.070). Among stage four patients, PBL had significantly longer median OS (24.1 versus 11.2 months, P = 0.015). Multivariable analysis among resected patients identified age >65 y (hazard ratio [HR] = 1.59; 95% confidence interval [CI]: 1.24-2.05), stage four disease (HR = 1.88; 95% CI: 1.18-2.99), positive lymph node ratio (1%-20%: HR = 2.38; 95% CI: 1.65-3.42; >20%: HR = 1.84; 95% CI: 1.31-2.58), and R1 margins (HR = 1.79; 95% CI: 1.24-2.59) as predictors of higher mortality. Adjuvant chemotherapy was associated with improved survival (HR = 0.68; 95% CI: 0.52-0.88). pACC and PBL share similar presentations, but PBL patients exhibit higher resection rates and better stage four survival. Complete resection and adjuvant chemotherapy independently predict improved survival in both groups.

8 September 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
JQJiage Qian
Jiage Qian
SCSebastiaan Ceuppens
Sebastiaan Ceuppens
NTNikhil V. Tirukkovalur
Nikhil V. Tirukkovalur
KLKenneth K. Lee
Kenneth K. Lee
AZAmer H. Zureikat
Amer H. Zureikat
APAlessandro Paniccia
Alessandro Paniccia
Prior evidence suggests higher postoperative complications in pancreatic neuroendocrine tumors (pNET) compared to ductal adenocarcinoma (PDAC). This study refines the comparison using the Ideal Outcome (IO) metric and identifies predictors of IO. A retrospective cohort study was performed using the 2014-2023 standard and pancreas-targeted ACS-NSQIP database to identify patients with PDAC or pNET who underwent pancreatoduodenectomy (PD) or distal pancreatectomy (DP). IO was defined as absence of clinically relevant postoperative pancreatic fistula (CR-POPF), prolonged length of stay (LOS), severe complications, reoperation, readmission, and mortality. A total of 25,290 PDAC and 4914 pNET patients were included. In PD, IO was lower in pNET (44.2 %) compared to PDAC (56.9 %, p < 0.001), with pNET having higher rates of severe complications (31.2 % vs. 19.0 %, p < 0.001), prolonged LOS (28.9 % vs. 25.8 %; p = 0.004), CR-POPF (26.7 % vs. 10.9 %; p < 0.001), and readmission (23.6 % vs. 15.3 %; p < 0.001). In contrast, pNET had higher IO after DP (60.1 % vs. 57.1 %; p = 0.008), with higher CR-POPF (19.2 % vs. 13.4 %; p < 0.001) but lower prolonged LOS (18.5 % vs. 26.4 %; p < 0.001). In PD, predictors of lower IO for both histologies included male sex (PDAC aOR 0.83; pNET 0.60), obesity (0.77; 0.63), hypertension (0.89; 0.79), small duct (0.81; 0.75), and soft gland (0.62; 0.57). In DP, minimally invasive surgery was associated with higher IO in both cancer types (PDAC aOR 1.71; pNET 1.52; all p < 0.05). Compared to PDAC, IO rate for pNET was lower after PD but higher after DP. CR-POPF was consistently higher in pNET, while other components of IO varied by procedure.

31 July 2025 in Journal of Surgical Oncology
Verified
Journal Article
Open access
JQJiage Qian
Jiage Qian
NTNikhil V. Tirukkovalur
Nikhil V. Tirukkovalur
JZJanie Y. Zhang
Janie Y. Zhang
ASAnwaar Saeed
Anwaar Saeed
SCSebastiaan Ceuppens
Sebastiaan Ceuppens
APAlessandro Paniccia
Alessandro Paniccia
Background: Many patients with resectable pancreatic ductal adenocarcinoma (PDAC) treated with modified FOLFIRINOX (mFOLFIRINOX) require dose reduction due to adverse effects. This study explores the optimal threshold for mFOLFIRINOX relative dose intensity (RDI) and characterizes RDI's correlation with CA 19‐9.Methods: A single‐institution retrospective analysis of 97 patients with PDAC treated with mFOLFIRINOX and pancreatectomy from 2017 to 2022. RDI was calculated by dividing the delivered dose intensity by the intended dose intensity over 6 months.Results: Median overall RDI was 73.8% (fluorouracil 75.5%, irinotecan 74.5%, oxaliplatin 70.6%). An RDI cutoff of ≥ 70% (n = 57) was associated with significantly improved overall survival (median OS: 62.6 vs. 43.7 months, p = 0.034). Compared to patients with < 70% RDI who did not achieve CA 19‐9 normalization, those with ≥ 70% RDI and normalization had significantly improved survival (HR: 0.27; 95% CI: 0.11–0.73). No significant benefit was observed with ≥ 70% RDI without CA 19‐9 normalization or < 70% RDI with normalization. In the multivariable model, RDI ≥ 70% remained independently associated with improved OS (HR = 0.37, 95% CI: 0.18–0.79) but not disease‐free survival (HR = 0.50, 95% CI: 0.24–1.03).Conclusion: Receiving ≥ 70% RDI of mFOLFIRINOX and CA 19‐9 normalization independently improves survival in resected PDAC. The greatest benefit is observed when both are achieved.